Reports Q3 revenue $83.3M, consensus $80.77M. “In my initial weeks as CEO, I am pleased to report we delivered a strong performance. We accelerated U.S. system placements, demonstrating strong demand for the HYDROS(R) Robotic System, and achieved 43% year over year global revenue growth,” said Larry Wood, chief executive officer. “This quarter’s results underscore the strength of our business and the growing adoption of Aquablation therapy. My first two months at PROCEPT have only deepened my confidence in our significant growth potential. We remain focused on expanding awareness of Aquablation(R) therapy, driving patient activation and advancing our mission.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRCT:
- PRCT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Procept Biorobotics’ WATER IV Study: A Game Changer in Prostate Cancer Treatment?
- Procept Biorobotics’ Aquablation Therapy Study: A Potential Game-Changer for Prostate Treatment
- Buy Rating Affirmed Amid Potential Upside and Strategic Leadership Changes
- Procept BioRobotics price target lowered to $50 from $64 at Truist